Furthermore, SRC has also been identified as a potential driver of resistance to paclitaxel in ovarian cancer cells, and SRC inhibition enhances the antitumour and antiangiogenic effects of paclitaxel [13–15]. Here, SRC is linked to ovarian carcinoma.